

Listing 16.2.1-1-1: Listing of subjects disposition - BNT162b1

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
1 µg Younger	10015	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020	23APR2020 10JUN2020 22JUL2020	23APR2020	29APR2020	20MAY2020	17JUN2020			
	10018	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020	23APR2020 10JUN2020 21JUL2020	23APR2020	29APR2020	20MAY2020	17JUN2020			
	10023	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020	24APR2020 16JUN2020 28JUL2020	24APR2020	05MAY2020	26MAY2020	22JUN2020			
	10025	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020	24APR2020 16JUN2020 28JUL2020	24APR2020	05MAY2020	26MAY2020	22JUN2020			
	10033	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020	27APR2020 16JUN2020 28JUL2020	27APR2020	05MAY2020	26MAY2020	22JUN2020			
	10036	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020	27APR2020 04JUN2020 31JUL2020	27APR2020	08MAY2020	29MAY2020	25JUN2020			
	10040	3.0, 17 Apr 2020 5.0, 26 MAY 2020	28APR2020 04JUN2020	28APR2020	08MAY2020	29MAY2020	25JUN2020			
Program: Lbase_Dispatch_1.sas (Page 1 of 18)										

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-1: Listing of subjects disposition - BNT162b1

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
1 µg Younger	10041	3.0, 17 Apr 2020 5.0, 26 MAY 2020	28APR2020 04JUN2020	28APR2020	08MAY2020	29MAY2020	25JUN2020			
	10042	3.0, 17 Apr 2020 5.0, 26 MAY 2020	28APR2020 04JUN2020	28APR2020	08MAY2020	29MAY2020	25JUN2020			
	10045	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020	28APR2020 16JUN2020 28JUL2020	28APR2020	05MAY2020	26MAY2020	23JUN2020			
	10048	3.0, 17 Apr 2020 5.0, 26 MAY 2020	28APR2020 04JUN2020	28APR2020	08MAY2020	29MAY2020	25JUN2020			
	10052	3.0, 17 Apr 2020 5.0, 26 MAY 2020	05MAY2020 03JUN2020	05MAY2020	08MAY2020	29MAY2020	03JUL2020			
3 µg Younger	10170	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	02JUL2020 30JUL2020 07AUG2020 18SEP2020	02JUL2020	31JUL2020	21AUG2020	18SEP2020			
	10194	7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	13JUL2020 12AUG2020 14OCT2020	13JUL2020	22JUL2020	12AUG2020	08SEP2020			
Program: Lbase_Disposition_1.sas (Page 2 of 18)										

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-1: Listing of subjects disposition - BNT162b1

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
3 µg Younger	10198	7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	15JUL2020 12AUG2020 14OCT2020	15JUL2020	22JUL2020	12AUG2020	08SEP2020			
	10200	7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	15JUL2020 12AUG2020 14OCT2020	15JUL2020	22JUL2020	12AUG2020	08SEP2020			
	10204	7.0, 26 JUN 2020 8.0, 21 JUL 2020	15JUL2020 12AUG2020	15JUL2020	22JUL2020	12AUG2020	08SEP2020			
	10209	7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	17JUL2020 12AUG2020 14OCT2020	17JUL2020	22JUL2020	12AUG2020	08SEP2020			
	10212	7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	17JUL2020 12AUG2020 14OCT2020	17JUL2020	22JUL2020	12AUG2020	08SEP2020			
	10221	7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	24JUL2020 07AUG2020 18SEP2020	24JUL2020	31JUL2020	21AUG2020	18SEP2020			
	10224	7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	24JUL2020 07AUG2020 18SEP2020	24JUL2020	31JUL2020	21AUG2020	18SEP2020			

Program: Lbase_Disposition_1.sas (Page 3 of 18)

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-1: Listing of subjects disposition - BNT162b1

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
3 µg Younger	10225	7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	24JUL2020 07AUG2020 18SEP2020	24JUL2020	31JUL2020	21AUG2020	18SEP2020			
	10226	7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	24JUL2020 07AUG2020 18SEP2020	24JUL2020	31JUL2020	21AUG2020	18SEP2020			
	10227	7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	24JUL2020 07AUG2020 18SEP2020	24JUL2020	31JUL2020	21AUG2020	18SEP2020			
10 µg Younger	10001	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020	22APR2020 04JUN2020 17JUL2020 23OCT2020	22APR2020	24APR2020	15MAY2020	12JUN2020	23OCT2020		
	10003	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020	22APR2020 09JUN2020 21JUL2020	22APR2020	28APR2020	19MAY2020	17JUN2020			
	10004	3.0, 17 Apr 2020 5.0, 26 MAY 2020 8.0, 21 JUL 2020	22APR2020 04JUN2020 23OCT2020	22APR2020	24APR2020	15MAY2020	12JUN2020			
	10005	3.0, 17 Apr 2020 5.0, 26 MAY 2020	22APR2020 04JUN2020	22APR2020	24APR2020	15MAY2020	12JUN2020	23OCT2020		
Program: Lbase_Disposition_1.sas (Page 4 of 18)										

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-1: Listing of subjects disposition - BNT162b1

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
10 µg Younger	10006	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020	22APR2020 09JUN2020 21JUL2020	22APR2020	28APR2020	19MAY2020	17JUN2020			
	10007	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020	22APR2020 04JUN2020 17JUL2020 23OCT2020	22APR2020	23APR2020	14MAY2020	12JUN2020			
	10008	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020	22APR2020 09JUN2020 21JUL2020	22APR2020	28APR2020	19MAY2020	17JUN2020			
	10009	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020	22APR2020 09JUN2020 21JUL2020	22APR2020	28APR2020	19MAY2020	17JUN2020			
	10010	3.0, 17 Apr 2020	22APR2020	22APR2020	24APR2020				19MAY2020	Adverse Event
	10011	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020	22APR2020 04JUN2020 17JUL2020	22APR2020	24APR2020	15MAY2020	12JUN2020	23OCT2020		
	10017	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020	23APR2020 09JUN2020 21JUL2020	23APR2020	28APR2020	19MAY2020	17JUN2020			

Program: Lbase_Disposition_1.sas (Page 5 of 18)

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-1: Listing of subjects disposition - BNT162b1

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
10 µg Younger	10019	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020	23APR2020 09JUN2020 21JUL2020	23APR2020	28APR2020	19MAY2020	17JUN2020			
20 µg Younger	10151	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	17JUN2020 16JUL2020 13AUG2020 09OCT2020	17JUN2020	16JUL2020	06AUG2020	03SEP2020			
	10171	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	07JUL2020 16JUL2020 13AUG2020 09OCT2020	07JUL2020	16JUL2020	06AUG2020	03SEP2020			
	10172	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	07JUL2020 16JUL2020 13AUG2020 15OCT2020	07JUL2020	16JUL2020	06AUG2020	02SEP2020			
	10173	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	07JUL2020 16JUL2020 13AUG2020 09OCT2020	07JUL2020	16JUL2020	06AUG2020	02SEP2020			
	10175	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	07JUL2020 16JUL2020 13AUG2020 09OCT2020	07JUL2020	16JUL2020	06AUG2020	03SEP2020			
	10176	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020	07JUL2020 16JUL2020 13AUG2020	07JUL2020	16JUL2020	06AUG2020	03SEP2020			
Program: Lbase_Disposition_1.sas (Page 6 of 18)										

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-1: Listing of subjects disposition - BNT162b1

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
20 µg Younger	10178	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020	07JUL2020 16JUL2020 13AUG2020	07JUL2020	16JUL2020	06AUG2020			09SEP2020	Other
	10179	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	09JUL2020 16JUL2020 13AUG2020 09OCT2020	09JUL2020	16JUL2020	06AUG2020	03SEP2020			
	10181	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	09JUL2020 16JUL2020 13AUG2020 14OCT2020	09JUL2020	16JUL2020	06AUG2020	03SEP2020			
	10182	5.0, 26 MAY 2020 7.0, 26 JUN 2020	09JUL2020 16JUL2020	09JUL2020	16JUL2020				23JUL2020	Withdrawal By Subject
	10183	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	09JUL2020 16JUL2020 13AUG2020 09OCT2020	09JUL2020	16JUL2020	06AUG2020	03SEP2020			
	10197	7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	13JUL2020 13AUG2020 09OCT2020	13JUL2020	16JUL2020	06AUG2020	03SEP2020			
30 µg Younger	10016	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020	23APR2020 10JUN2020 22JUL2020	23APR2020	29APR2020	20MAY2020	17JUN2020			
Program: Lbase_Dispatch_1.sas (Page 7 of 18)										

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-1: Listing of subjects disposition - BNT162b1

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
30 µg Younger	10020	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020	24APR2020 10JUN2020 22JUL2020	24APR2020	29APR2020	20MAY2020	17JUN2020			
	10021	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020	24APR2020 16JUN2020 28JUL2020	24APR2020	05MAY2020	26MAY2020	22JUN2020			
	10028	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020	27APR2020 04JUN2020 30JUL2020	27APR2020	07MAY2020	28MAY2020	25JUN2020			
	10031	3.0, 17 Apr 2020 5.0, 26 MAY 2020	27APR2020 04JUN2020	27APR2020	07MAY2020	28MAY2020	27JUN2020			
	10032	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020	27APR2020 16JUN2020 28JUL2020	27APR2020	05MAY2020	26MAY2020	22JUN2020			
	10034	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020	27APR2020 16JUN2020 28JUL2020	27APR2020	05MAY2020	26MAY2020	22JUN2020			
	10037	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020	27APR2020 16JUN2020 28JUL2020	27APR2020	05MAY2020	26MAY2020	22JUN2020			
Program: Lbase_Disposition_1.sas (Page 8 of 18)										

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-1: Listing of subjects disposition - BNT162b1

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
30 µg Younger	10038	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020	27APR2020 04JUN2020 24JUL2020	27APR2020	07MAY2020	28MAY2020	25JUN2020			
	10039	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020	27APR2020 04JUN2020 30JUL2020	27APR2020	07MAY2020	28MAY2020	25JUN2020			
	10043	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020	28APR2020 03JUN2020 30JUL2020	28APR2020	07MAY2020	28MAY2020	25JUN2020			
	10047	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020	28APR2020 04JUN2020 30JUL2020	28APR2020	07MAY2020	28MAY2020	25JUN2020			
50 µg Younger	10049	3.0, 17 Apr 2020 5.0, 26 MAY 2020	05MAY2020 09JUN2020	05MAY2020	12MAY2020	02JUN2020	30JUN2020			
	10050	3.0, 17 Apr 2020	05MAY2020	05MAY2020	15MAY2020				03JUN2020	Other
	10053	3.0, 17 Apr 2020 5.0, 26 MAY 2020	05MAY2020 09JUN2020	05MAY2020	12MAY2020	02JUN2020	30JUN2020			
Program: Lbase_Dispatch_1.sas (Page 9 of 18)										

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-1: Listing of subjects disposition - BNT162b1

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
50 µg Younger	10055	3.0, 17 Apr 2020 5.0, 26 MAY 2020	07MAY2020 03JUN2020	07MAY2020	13MAY2020	03JUN2020	30JUN2020			
	10056	3.0, 17 Apr 2020 5.0, 26 MAY 2020	07MAY2020 03JUN2020	07MAY2020	13MAY2020	03JUN2020	30JUN2020			
	10057	3.0, 17 Apr 2020 5.0, 26 MAY 2020 8.0, 21 JUL 2020	07MAY2020 05JUN2020 11AUG2020	07MAY2020	15MAY2020	05JUN2020	03JUL2020			
	10059	3.0, 17 Apr 2020 5.0, 26 MAY 2020	07MAY2020 03JUN2020	07MAY2020	13MAY2020	03JUN2020	30JUN2020			
	10060	3.0, 17 Apr 2020 5.0, 26 MAY 2020	07MAY2020 03JUN2020	07MAY2020	13MAY2020	03JUN2020	30JUN2020			
	10067	3.0, 17 Apr 2020 5.0, 26 MAY 2020 8.0, 21 JUL 2020	08MAY2020 05JUN2020 07AUG2020	08MAY2020	15MAY2020	05JUN2020	03JUL2020			
	10068	3.0, 17 Apr 2020 5.0, 26 MAY 2020 8.0, 21 JUL 2020	08MAY2020 05JUN2020 11AUG2020	08MAY2020	15MAY2020	05JUN2020	03JUL2020			
Program: Lbase_Dispatch_1.sas (Page 10 of 18)										

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-1: Listing of subjects disposition - BNT162b1

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
50 µg Younger	10070	3.0, 17 Apr 2020 5.0, 26 MAY 2020 8.0, 21 JUL 2020	08MAY2020 05JUN2020 07AUG2020	08MAY2020	15MAY2020	05JUN2020	03JUL2020			
	10073	3.0, 17 Apr 2020 5.0, 26 MAY 2020 8.0, 21 JUL 2020	11MAY2020 05JUN2020 07AUG2020	11MAY2020	15MAY2020	05JUN2020	03JUL2020			
60 µg Younger	10066	3.0, 17 Apr 2020 5.0, 26 MAY 2020 8.0, 21 JUL 2020	08MAY2020 09JUN2020 12AUG2020	08MAY2020	19MAY2020		07JUL2020			
	10075	3.0, 17 Apr 2020 5.0, 26 MAY 2020 8.0, 21 JUL 2020	11MAY2020 12JUN2020 14AUG2020	11MAY2020	22MAY2020		10JUL2020			
	10076	3.0, 17 Apr 2020 5.0, 26 MAY 2020 8.0, 21 JUL 2020	11MAY2020 12JUN2020 14AUG2020	11MAY2020	22MAY2020		10JUL2020			
	10078	3.0, 17 Apr 2020 5.0, 26 MAY 2020 8.0, 21 JUL 2020	11MAY2020 12JUN2020 07AUG2020	11MAY2020	22MAY2020		10JUL2020			
	10083	3.0, 17 Apr 2020 5.0, 26 MAY 2020 8.0, 21 JUL 2020	12MAY2020 10JUN2020 12AUG2020	12MAY2020	20MAY2020		07JUL2020			
Program: Lbase_Disposition_1.sas (Page 11 of 18)										

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-1: Listing of subjects disposition - BNT162b1

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
60 µg Younger	10084	3.0, 17 Apr 2020 5.0, 26 MAY 2020 8.0, 21 JUL 2020	12MAY2020 12JUN2020 14AUG2020	12MAY2020	22MAY2020		10JUL2020			
	10085	3.0, 17 Apr 2020 5.0, 26 MAY 2020 8.0, 21 JUL 2020	12MAY2020 12JUN2020 14AUG2020	12MAY2020	22MAY2020		10JUL2020			
	10089	3.0, 17 Apr 2020 5.0, 26 MAY 2020 8.0, 21 JUL 2020	12MAY2020 10JUN2020 12AUG2020	12MAY2020	20MAY2020		07JUL2020			
	10093	3.0, 17 Apr 2020 5.0, 26 MAY 2020 8.0, 21 JUL 2020	12MAY2020 10JUN2020 12AUG2020	12MAY2020	20MAY2020		07JUL2020			
	10096	3.0, 17 Apr 2020 5.0, 26 MAY 2020 8.0, 21 JUL 2020	12MAY2020 09JUN2020 12AUG2020	12MAY2020	19MAY2020		07JUL2020			
	10103	3.0, 17 Apr 2020 5.0, 26 MAY 2020 8.0, 21 JUL 2020	14MAY2020 12JUN2020 14AUG2020	14MAY2020	22MAY2020		10JUL2020			
	10104	3.0, 17 Apr 2020 5.0, 26 MAY 2020 8.0, 21 JUL 2020	14MAY2020 10JUN2020 12AUG2020	14MAY2020	20MAY2020		07JUL2020			
Program: Lbase_Disp_1.sas (Page 12 of 18)										

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-1: Listing of subjects disposition - BNT162b1

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
10 µg Older	10273	8.0, 21 JUL 2020 8.0, 21 JUL 2020	12AUG2020 17SEP2020	12AUG2020	27AUG2020	17SEP2020	15OCT2020			
	10274	8.0, 21 JUL 2020 8.0, 21 JUL 2020	12AUG2020 17SEP2020	12AUG2020	27AUG2020	17SEP2020	15OCT2020			
	10282	8.0, 21 JUL 2020	14AUG2020	14AUG2020	20AUG2020	10SEP2020	08OCT2020			
	10283	8.0, 21 JUL 2020 8.0, 21 JUL 2020	14AUG2020 17SEP2020	14AUG2020	27AUG2020	17SEP2020	15OCT2020			
	10286	8.0, 21 JUL 2020 8.0, 21 JUL 2020	14AUG2020 15SEP2020	14AUG2020	25AUG2020	15SEP2020				
	10287	8.0, 21 JUL 2020 8.0, 21 JUL 2020	14AUG2020 15SEP2020	14AUG2020	25AUG2020	15SEP2020	13OCT2020			
	10288	8.0, 21 JUL 2020 8.0, 21 JUL 2020	14AUG2020 15SEP2020	14AUG2020	25AUG2020	15SEP2020	13OCT2020			
Program: Lbase_Disposition_1.sas (Page 13 of 18)										

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-1: Listing of subjects disposition - BNT162b1

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
10 µg Older	10289	8.0, 21 JUL 2020 8.0, 21 JUL 2020	14AUG2020 17SEP2020	14AUG2020	20AUG2020	10SEP2020	08OCT2020			
	10291	8.0, 21 JUL 2020 8.0, 21 JUL 2020	14AUG2020 15SEP2020	14AUG2020	25AUG2020	15SEP2020	13OCT2020			
	10292	8.0, 21 JUL 2020 8.0, 21 JUL 2020	14AUG2020 17SEP2020	14AUG2020	27AUG2020	17SEP2020	15OCT2020			
	10298	8.0, 21 JUL 2020 8.0, 21 JUL 2020	17AUG2020 17SEP2020	17AUG2020	27AUG2020	17SEP2020	15OCT2020			
	10320	8.0, 21 JUL 2020 8.0, 21 JUL 2020	24AUG2020 17SEP2020	24AUG2020	27AUG2020	17SEP2020	15OCT2020			
20 µg Older	20207	8.0, 21 JUL 2020 8.0, 21 JUL 2020	10AUG2020 15SEP2020	10AUG2020	09SEP2020	30SEP2020				
	20211	8.0, 21 JUL 2020 8.0, 21 JUL 2020	10AUG2020 15SEP2020	10AUG2020	08SEP2020	30SEP2020				
Program: Lbase_Dispatch_1.sas (Page 14 of 18)										

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-1: Listing of subjects disposition - BNT162b1

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
20 µg Older	20220	8.0, 21 JUL 2020 8.0, 21 JUL 2020	14AUG2020 15SEP2020	14AUG2020	08SEP2020	30SEP2020				
	20227	8.0, 21 JUL 2020 8.0, 21 JUL 2020	19AUG2020 12SEP2020	19AUG2020	11SEP2020	02OCT2020				
	20234	8.0, 21 JUL 2020 8.0, 21 JUL 2020	27AUG2020 15SEP2020	27AUG2020	09SEP2020	30SEP2020				
	20236	8.0, 21 JUL 2020 8.0, 21 JUL 2020	27AUG2020 12SEP2020	27AUG2020	11SEP2020	02OCT2020				
	20237	8.0, 21 JUL 2020 8.0, 21 JUL 2020	27AUG2020 12SEP2020	27AUG2020	11SEP2020	02OCT2020				
	20238	8.0, 21 JUL 2020 8.0, 21 JUL 2020	27AUG2020 12SEP2020	27AUG2020	11SEP2020	02OCT2020				
	20239	8.0, 21 JUL 2020 8.0, 21 JUL 2020	28AUG2020 12SEP2020	28AUG2020	11SEP2020	02OCT2020				
Program: Lbase_Dispatch_1.sas (Page 15 of 18)										

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-1: Listing of subjects disposition - BNT162b1

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
20 µg Older	20241	8.0, 21 JUL 2020 8.0, 21 JUL 2020	28AUG2020 15SEP2020	28AUG2020	09SEP2020	30SEP2020				
	20242	8.0, 21 JUL 2020 8.0, 21 JUL 2020	28AUG2020 15SEP2020	28AUG2020	09SEP2020					
	20243	8.0, 21 JUL 2020 8.0, 21 JUL 2020	28AUG2020 12SEP2020	28AUG2020	11SEP2020	02OCT2020				
30 µg Older	10350	8.0, 21 JUL 2020	14SEP2020	14SEP2020	25SEP2020	16OCT2020				
	10351	8.0, 21 JUL 2020	14SEP2020	14SEP2020	25SEP2020	16OCT2020				
	10352	8.0, 21 JUL 2020	14SEP2020	14SEP2020	22SEP2020	13OCT2020				
	10353	8.0, 21 JUL 2020	14SEP2020	14SEP2020	22SEP2020	13OCT2020				
Program: Lbase_Disposition_1.sas (Page 16 of 18)										

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-1: Listing of subjects disposition - BNT162b1

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
30 µg Older	10358	8.0, 21 JUL 2020	14SEP2020	14SEP2020	23SEP2020	14OCT2020				
	10360	8.0, 21 JUL 2020	14SEP2020	14SEP2020	23SEP2020	14OCT2020				
	10361	8.0, 21 JUL 2020	14SEP2020	14SEP2020	25SEP2020	16OCT2020				
	10362	8.0, 21 JUL 2020	14SEP2020	14SEP2020	25SEP2020	16OCT2020				
	10363	8.0, 21 JUL 2020	14SEP2020	14SEP2020	25SEP2020	16OCT2020				
	10364	8.0, 21 JUL 2020	14SEP2020	14SEP2020	25SEP2020	16OCT2020				
	10365	8.0, 21 JUL 2020	14SEP2020	14SEP2020	23SEP2020	14OCT2020				
Program: Lbase_Disposition_1.sas (Page 17 of 18)										

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-1: Listing of subjects disposition - BNT162b1

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
30 µg Older	10366	8.0, 21 JUL 2020	14SEP2020	14SEP2020	23SEP2020	14OCT2020				
Program: Lbase_Disposition_1.sas (Page 18 of 18)										

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-5-1: Listing of subjects demographics - BNT162b1

Safety set

Dose group	Subject number	Age [years]	Gender	Ethnicity	Race	Height [cm]	Weight [kg]	BMI [kg/m2]
1 µg Younger	10015	53.50	Female	Not Hispanic or Latino	White	160	64.2	25.1
	10018	21.42	Female	Not Hispanic or Latino	White	169	62	21.7
	10023	33.08	Female	Not Hispanic or Latino	White	169	71	24.9
	10025	35.92	Male	Not Hispanic or Latino	White	181	97	29.6
	10033	44.75	Male	Not Hispanic or Latino	White	183	93.4	27.9
	10036	40.58	Female	Not Hispanic or Latino	White	166	58.3	21.2
	10040	41.08	Male	Not Hispanic or Latino	White	171	78.3	26.8
	10041	40.17	Female	Hispanic or Latino	White	152	50.1	21.7
	10042	39.50	Female	Not Hispanic or Latino	White	165	70	25.7
	10045	24.00	Female	Not Hispanic or Latino	White	166	70.5	25.6
	10048	28.75	Male	Not Hispanic or Latino	White	179	93.1	29.1
	10052	55.75	Male	Not Hispanic or Latino	White	173	68	22.7
3 µg Younger	10170	53.92	Male	Not Hispanic or Latino	White	178	76.5	24.1
	10194	33.17	Female	Not Hispanic or Latino	White	172	62.8	21.2
	10198	49.50	Female	Not Hispanic or Latino	White	177	85.6	27.3
	10200	47.00	Male	Not Hispanic or Latino	White	172	64.2	21.7
	10204	55.17	Male	Not Hispanic or Latino	White	181	81.9	25
	10209	49.92	Female	Not Hispanic or Latino	White	172	78.8	26.6
	10212	50.33	Female	Not Hispanic or Latino	White	176	87	28.1
Program: Lbase_Demo_5.sas (Page 1 of 7)								

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

090177e196971658\Approved\Approved On: 23-Mar-2021 06:32 (GMT)

Listing 16.2.1-5-1: Listing of subjects demographics - BNT162b1

Safety set

Dose group	Subject number	Age [years]	Gender	Ethnicity	Race	Height [cm]	Weight [kg]	BMI [kg/m2]
3 µg Younger	10221	31.33	Male	Not Hispanic or Latino	White	180	81.3	25.1
	10224	23.83	Female	Not Hispanic or Latino	White	170	71.4	24.7
	10225	43.00	Male	Not Hispanic or Latino	White	194	110.2	29.3
	10226	24.42	Female	Not Hispanic or Latino	White	166	57.6	20.9
	10227	35.75	Male	Not Hispanic or Latino	White	164	68	25.3
10 µg Younger	10001	51.17	Female	Not Hispanic or Latino	White	171	75.4	25.8
	10003	36.25	Female	Not Hispanic or Latino	White	155	55.3	23
	10004	55.00	Male	Not Hispanic or Latino	White	193	100.5	27
	10005	33.67	Female	Not Hispanic or Latino	White	171	68	23.3
	10006	52.25	Female	Not Hispanic or Latino	White	171	75	25.6
	10007	29.67	Male	Not Hispanic or Latino	Black or African American	177	76.1	24.3
	10008	25.08	Female	Not Hispanic or Latino	White	165	57.8	21.2
	10009	42.00	Male	Not Hispanic or Latino	White	178	91	28.7
	10010	53.08	Female	Not Hispanic or Latino	White	166	65.1	23.6
	10011	54.83	Female	Not Hispanic or Latino	White	168	62.4	22.1
	10017	36.17	Female	Not Hispanic or Latino	White	161	54.5	21
	10019	54.25	Male	Not Hispanic or Latino	White	177	77.7	24.8
20 µg Younger	10151	52.08	Male	Not Hispanic or Latino	White	187	72.2	20.6
	10171	30.50	Male	Not Hispanic or Latino	White	179	72.5	22.6
Program: Lbase_Demo_5.sas (Page 2 of 7)								

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-5-1: Listing of subjects demographics - BNT162b1

Safety set

Dose group	Subject number	Age [years]	Gender	Ethnicity	Race	Height [cm]	Weight [kg]	BMI [kg/m2]
20 µg Younger	10172	39.33	Female	Not Hispanic or Latino	White	159	55.1	21.8
	10173	36.33	Male	Not Hispanic or Latino	White	192	103.7	28.1
	10175	36.00	Male	Not Hispanic or Latino	White	182	78.6	23.7
	10176	24.17	Male	Not Hispanic or Latino	White	163	60.2	22.7
	10178	20.92	Female	Not Hispanic or Latino	White	167	71.7	25.7
	10179	49.33	Male	Not Hispanic or Latino	White	170	67.3	23.3
	10181	54.08	Male	Not Hispanic or Latino	Asian	176	75.5	24.4
	10182	38.67	Female	Not Hispanic or Latino	White	171	80.5	27.5
	10183	55.83	Female	Not Hispanic or Latino	White	171	73	25
	10197	35.83	Male	Not Hispanic or Latino	White	165	72.6	26.7
30 µg Younger	10016	26.33	Female	Not Hispanic or Latino	White	170	61.3	21.2
	10020	42.92	Female	Not Hispanic or Latino	White	166	79	28.7
	10021	34.50	Male	Not Hispanic or Latino	White	184	97	28.7
	10028	42.58	Female	Not Hispanic or Latino	White	162	77	29.3
	10031	23.92	Male	Not Hispanic or Latino	White	167	66.7	23.9
	10032	35.83	Male	Not Hispanic or Latino	White	179	95.4	29.8
	10034	42.00	Male	Not Hispanic or Latino	White	189	96.8	27.1
	10037	54.00	Male	Not Hispanic or Latino	White	174	68.3	22.6
	10038	31.92	Male	Not Hispanic or Latino	White	179	91.7	28.6
Program: Lbase_Demo_5.sas (Page 3 of 7)								

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-5-1: Listing of subjects demographics - BNT162b1

Safety set

Dose group	Subject number	Age [years]	Gender	Ethnicity	Race	Height [cm]	Weight [kg]	BMI [kg/m2]
30 µg Younger	10039	32.00	Male	Not Hispanic or Latino	White	185	86.1	25.2
	10043	36.33	Female	Not Hispanic or Latino	White	171	59	20.2
	10047	26.58	Male	Not Hispanic or Latino	White	187	79.8	22.8
50 µg Younger	10049	46.42	Male	Not Hispanic or Latino	White	172	85.4	28.9
	10050	21.50	Female	Not Hispanic or Latino	White	178	76.6	24.2
	10053	28.75	Male	Not Hispanic or Latino	White	185	67.1	19.6
	10055	34.17	Female	Not Hispanic or Latino	White	170	80	27.7
	10056	24.50	Female	Not Hispanic or Latino	White	175	80	26.1
	10057	47.75	Male	Not Hispanic or Latino	White	180	78.8	24.3
	10059	26.67	Female	Not Hispanic or Latino	White	159	59.1	23.4
	10060	47.50	Male	Not Hispanic or Latino	White	172	84.9	28.7
	10067	30.33	Male	Not Hispanic or Latino	White	180	97	29.9
	10068	19.92	Female	Not Hispanic or Latino	White	164	60	22.3
	10070	47.83	Male	Not Hispanic or Latino	White	178	94.5	29.8
60 µg Younger	10073	31.25	Female	Not Hispanic or Latino	White	164	57.4	21.3
	10066	24.33	Male	Not Hispanic or Latino	White	179	65.7	20.5
	10075	27.92	Female	Not Hispanic or Latino	White	179	82.4	25.7
	10076	50.17	Female	Not Hispanic or Latino	White	162	62.2	23.7
	10078	53.17	Male	Not Hispanic or Latino	White	173	78.9	26.4
Program: Lbase_Demo_5.sas (Page 4 of 7)								

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-5-1: Listing of subjects demographics - BNT162b1

Safety set

Dose group	Subject number	Age [years]	Gender	Ethnicity	Race	Height [cm]	Weight [kg]	BMI [kg/m2]
60 µg Younger	10083	42.17	Female	Not Hispanic or Latino	White	179	76.8	24
	10084	32.33	Male	Not Hispanic or Latino	White	177	93.5	29.8
	10085	24.67	Male	Not Hispanic or Latino	White	190	71.5	19.8
	10089	52.33	Female	Not Hispanic or Latino	White	165	66.3	24.4
	10093	48.75	Male	Not Hispanic or Latino	White	192	105.6	28.6
	10096	20.92	Male	Hispanic or Latino	White	175	77.5	25.3
	10103	25.33	Female	Not Hispanic or Latino	Asian	163	66.5	25
	10104	27.58	Male	Not Hispanic or Latino	White	183	97.5	29.1
10 µg Older	10273	71.42	Female	Not Hispanic or Latino	White	162	55.6	21.2
	10274	67.33	Male	Not Hispanic or Latino	White	173	80.2	26.8
	10282	73.92	Female	Not Hispanic or Latino	White	164	67.9	25.2
	10283	61.42	Male	Not Hispanic or Latino	White	190	81.3	22.5
	10286	56.67	Female	Not Hispanic or Latino	White	169	75.7	26.5
	10287	65.08	Male	Not Hispanic or Latino	White	170	63.3	21.9
	10288	61.83	Female	Not Hispanic or Latino	White	156	62.9	25.8
	10289	69.00	Male	Not Hispanic or Latino	White	169	76.4	26.7
	10291	63.25	Male	Not Hispanic or Latino	White	172	74.1	25
	10292	56.08	Male	Not Hispanic or Latino	White	183	91.7	27.4
	10298	57.33	Male	Not Hispanic or Latino	White	170	78	27
Program: Lbase_Demo_5.sas (Page 5 of 7)								

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-5-1: Listing of subjects demographics - BNT162b1

Safety set

Dose group	Subject number	Age [years]	Gender	Ethnicity	Race	Height [cm]	Weight [kg]	BMI [kg/m2]
10 µg Older	10320	68.42	Female	Not Hispanic or Latino	White	164	55.7	20.7
20 µg Older	20207	66.08	Female	Not Hispanic or Latino	White	164	76	28.3
	20211	67.67	Female	Not Hispanic or Latino	White	153	58.2	24.9
	20220	70.75	Female	Not Hispanic or Latino	White	157	68.1	27.6
	20227	67.92	Female	Not Hispanic or Latino	White	167	63.6	22.8
	20234	57.00	Female	Not Hispanic or Latino	White	175	87.2	28.5
	20236	58.92	Male	Not Hispanic or Latino	White	178	79.1	25
	20237	67.08	Female	Not Hispanic or Latino	White	159	57.6	22.8
	20238	58.17	Female	Not Hispanic or Latino	White	169	81	28.4
	20239	59.33	Male	Not Hispanic or Latino	White	174	72.5	23.9
	20241	75.83	Female	Not Hispanic or Latino	White	165	64.1	23.5
	20242	70.50	Female	Not Hispanic or Latino	White	166	67.5	24.5
20243	68.67	Female	Not Hispanic or Latino	White	161	69.6	26.9	
30 µg Older	10350	57.83	Female	Not Hispanic or Latino	White	162	60.3	23
	10351	57.33	Male	Not Hispanic or Latino	White	177	73.6	23.5
	10352	68.00	Male	Not Hispanic or Latino	White	173	67.2	22.5
	10353	67.92	Female	Not Hispanic or Latino	White	162	67.2	25.6
	10358	73.67	Female	Not Hispanic or Latino	White	159	72.4	28.6
	10360	59.33	Female	Not Hispanic or Latino	White	159	60.5	23.9
Program: Lbase_Demo_5.sas (Page 6 of 7)								

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-5-1: Listing of subjects demographics - BNT162b1

Safety set

Dose group	Subject number	Age [years]	Gender	Ethnicity	Race	Height [cm]	Weight [kg]	BMI [kg/m2]
30 µg Older	10361	72.25	Female	Not Hispanic or Latino	White	167	67.7	24.3
	10362	76.75	Male	Not Hispanic or Latino	White	179	82.3	25.7
	10363	63.67	Female	Not Hispanic or Latino	White	155	63.4	26.4
	10364	66.75	Male	Not Hispanic or Latino	White	175	87.1	28.4
	10365	73.25	Female	Not Hispanic or Latino	White	156	69.5	28.6
	10366	69.17	Female	Not Hispanic or Latino	White	159	68.5	27.1
Program: Lbase_Demo_5.sas (Page 7 of 7)								

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-7-1: Listing of medical history - BNT162b1

Safety set

Dose group	Subject number	Sequence number	Abnormality/Disease	Preferred term	System organ class	Start date	End date	Ongoing
1 µg Younger	10041	1	Migraine	Migraine	Nervous system disorders	28APR2020		Yes
10 µg Younger	10011	1	Genital herpes intermittent	Genital herpes	Infections and infestations			Yes
	10017	1	Glaucoma	Glaucoma	Eye disorders	2017		Yes
20 µg Younger	10172	1	Endometriosis	Endometriosis	Reproductive system and breast disorders	DEC2017	DEC2017	
30 µg Younger	10047	1	Headache, periodic	Headache	Nervous system disorders	2013		Yes
50 µg Younger	10049	1	Herpes labialis intermittent	Oral herpes	Infections and infestations			Yes
10 µg Older	10289	1	Slight stenosis of the internal carotid artery left site	Carotid artery stenosis	Nervous system disorders	2017		Yes
20 µg Older	20207	1	Hysterectomy	Hysterectomy	Surgical and medical procedures	1991	1991	
		2	Menopause	Menopause	Social circumstances	1991	1991	
	20211	1	menopause	Menopause	Social circumstances	2005	2005	
Medical history is coded using MedDRA version 23.0.								
Program: Lbase_Mh_7.sas (Page 1 of 2)								

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-7-1: Listing of medical history - BNT162b1

Safety set

Dose group	Subject number	Sequence number	Abnormality/Disease	Preferred term	System organ class	Start date	End date	Ongoing
20 µg Older	20220	1	menopause	Menopause	Social circumstances	1999	1999	
	20234	1	Hysterectomy	Hysterectomy	Surgical and medical procedures	2000	2000	
	20237	1	hysterectomy	Hysterectomy	Surgical and medical procedures	1999	1999	
		2	menopause	Menopause	Social circumstances	1999	1999	
	20238	1	menopause	Menopause	Social circumstances	2015	2015	
	20241	1	Menopause	Menopause	Social circumstances	1999	1999	
	20242	1	Menopause	Menopause	Social circumstances	2004	2004	
	20243	1	Menopause	Menopause	Social circumstances	1999	1999	
30 µg Older	10358	1	Intermittent muscle cramps	Muscle spasms	Musculoskeletal and connective tissue disorders	1987		Yes
	10365	1	Polyarthrosis -> pain (ankles, knees, spinal chord)	Osteoarthritis	Musculoskeletal and connective tissue disorders	1980		Yes
Medical history is coded using MedDRA version 23.0. Program: Lbase_Mh_7.sas (Page 2 of 2)								

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-3: Listing of subjects disposition - BNT162b2

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
1 µg Younger	20153	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	12JUN2020 20JUL2020 11AUG2020 21SEP2020	12JUN2020	29JUN2020	20JUL2020	18AUG2020			
	20154	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	12JUN2020 20JUL2020 11AUG2020 21SEP2020	12JUN2020	29JUN2020	20JUL2020	18AUG2020			
	20157	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	12JUN2020 20JUL2020 11AUG2020 21SEP2020	12JUN2020	29JUN2020	20JUL2020	18AUG2020			
	20158	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	15JUN2020 13JUL2020 07AUG2020 06OCT2020	15JUN2020	13JUL2020	03AUG2020	31AUG2020			
	20160	5.0, 26 MAY 2020 7.0, 26 JUN 2020	15JUN2020 20JUL2020	15JUN2020	29JUN2020				30JUL2020	Withdrawal By Subject
Program: Lbase_Disp_1.sas (Page 1 of 20)										

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-3: Listing of subjects disposition - BNT162b2

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
1 µg Younger	20163	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	15JUN2020 20JUL2020 12AUG2020 21SEP2020	15JUN2020	29JUN2020	20JUL2020	18AUG2020			
	20164	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	19JUN2020 13JUL2020 10AUG2020 05OCT2020	19JUN2020	13JUL2020	03AUG2020	04SEP2020			
	20166	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	19JUN2020 20JUL2020 11AUG2020 18SEP2020	19JUN2020	29JUN2020	20JUL2020	18AUG2020			
	20171	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	22JUN2020 13JUL2020 11AUG2020 05OCT2020	22JUN2020	13JUL2020	03AUG2020	31AUG2020			
	20181	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	03JUL2020 27JUL2020 18AUG2020 15SEP2020	03JUL2020	28JUL2020	18AUG2020				

Program: Lbase_Disposition_1.sas (Page 2 of 20)

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-3: Listing of subjects disposition - BNT162b2

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
1 µg Younger	20188	7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	16JUL2020 18AUG2020 15SEP2020	16JUL2020	28JUL2020	18AUG2020				
	20189	7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	16JUL2020 18AUG2020 15SEP2020	16JUL2020	28JUL2020	18AUG2020	15SEP2020			
3 µg Younger	20176	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	03JUL2020 20JUL2020 18AUG2020 16SEP2020	03JUL2020	29JUL2020	18AUG2020	16SEP2020			
	20185	7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	13JUL2020 18AUG2020 16SEP2020	13JUL2020	29JUL2020	18AUG2020	16SEP2020			
	20191	7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	22JUL2020 07AUG2020 17SEP2020	22JUL2020	06AUG2020	26AUG2020	24SEP2020			
Program: Lbase_Disposition_1.sas (Page 3 of 20)										

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-3: Listing of subjects disposition - BNT162b2

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
3 µg Younger	20192	7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	22JUL2020 11AUG2020 15SEP2020	22JUL2020	28JUL2020	18AUG2020	15SEP2020			
	20193	7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	22JUL2020 18AUG2020 16SEP2020	22JUL2020	29JUL2020	18AUG2020	16SEP2020			
	20194	7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	22JUL2020 18AUG2020 16SEP2020	22JUL2020	29JUL2020	18AUG2020	16SEP2020			
	20195	7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	22JUL2020 07AUG2020 18SEP2020	22JUL2020	31JUL2020	19AUG2020				
	20197	7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	22JUL2020 18AUG2020 15SEP2020	22JUL2020	28JUL2020	18AUG2020	15SEP2020			
Program: Lbase_Disposition_1.sas (Page 4 of 20)										

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-3: Listing of subjects disposition - BNT162b2

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
3 µg Younger	20200	7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	27JUL2020 07AUG2020 18SEP2020	27JUL2020	30JUL2020	19AUG2020	18SEP2020			
	20201	7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	27JUL2020 07AUG2020 17SEP2020	27JUL2020	06AUG2020	26AUG2020	24SEP2020			
	20203	7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	27JUL2020 07AUG2020 18SEP2020	27JUL2020	31JUL2020	21AUG2020				
	20204	7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	28JUL2020 07AUG2020 18SEP2020	28JUL2020	31JUL2020	19AUG2020				
10 µg Younger	20101	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020	18MAY2020 15JUN2020 14JUL2020 08SEP2020	18MAY2020	16JUN2020	07JUL2020	04AUG2020			
Program: Lbase_Disposition_1.sas (Page 5 of 20)										

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-3: Listing of subjects disposition - BNT162b2

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
10 µg Younger	20102	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020	18MAY2020 15JUN2020 14JUL2020 08SEP2020	18MAY2020	16JUN2020	07JUL2020	04AUG2020			
	20103	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020	18MAY2020 15JUN2020 13JUL2020 07SEP2020	18MAY2020	15JUN2020	06JUL2020	03AUG2020			
	20104	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020	18MAY2020 15JUN2020 14JUL2020 14SEP2020	18MAY2020	16JUN2020	07JUL2020	04AUG2020			
	20105	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020	18MAY2020 15JUN2020 14JUL2020 08SEP2020	18MAY2020	16JUN2020	06JUL2020	04AUG2020			
	20110	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020	19MAY2020 15JUN2020 14JUL2020 07AUG2020	19MAY2020	16JUN2020	07JUL2020	07AUG2020			

Program: Lbase_Disposition_1.sas (Page 6 of 20)

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-3: Listing of subjects disposition - BNT162b2

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
10 µg Younger	20111	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020	19MAY2020 15JUN2020 15JUL2020 04SEP2020	19MAY2020	18JUN2020	15JUL2020	06AUG2020			
	20114	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020	19MAY2020 15JUN2020 16JUL2020 07AUG2020	19MAY2020	18JUN2020	09JUL2020	07AUG2020			
	20116	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020	20MAY2020 17JUN2020 16JUL2020	20MAY2020	18JUN2020				16JUL2020	Adverse Event
	20117	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020	20MAY2020 17JUN2020 13JUL2020 10SEP2020	20MAY2020	18JUN2020	09JUL2020	06AUG2020			
	20118	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020	20MAY2020 17JUN2020 16JUL2020 10SEP2020	20MAY2020	18JUN2020	09JUL2020	06AUG2020			
Program: Lbase_Dispatch_1.sas (Page 7 of 20)										

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-3: Listing of subjects disposition - BNT162b2

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
10 µg Younger	20121	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020	20MAY2020 17JUN2020 16JUL2020 10SEP2020	20MAY2020	18JUN2020	09JUL2020	06AUG2020			
20 µg Younger	20156	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	12JUN2020 23JUL2020 13AUG2020 24SEP2020	12JUN2020	02JUL2020	23JUL2020	20AUG2020			
	20159	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	15JUN2020 22JUL2020 07AUG2020 23SEP2020	15JUN2020	01JUL2020	22JUL2020	19AUG2020			
	20168	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	19JUN2020 22JUL2020 12AUG2020 23SEP2020	19JUN2020	01JUL2020	22JUL2020	19AUG2020			
	20172	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	22JUN2020 23JUL2020 13AUG2020 24SEP2020	22JUN2020	02JUL2020	23JUL2020	20AUG2020			

Program: Lbase_Disposition_1.sas (Page 8 of 20)

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-3: Listing of subjects disposition - BNT162b2

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
20 µg Younger	20173	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	30JUN2020 14JUL2020 13AUG2020 24SEP2020	30JUN2020	02JUL2020	23JUL2020	20AUG2020			
	20174	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	03JUL2020 13JUL2020 17AUG2020 28SEP2020	03JUL2020	06JUL2020	27JUL2020	24AUG2020			
	20175	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	03JUL2020 13JUL2020 17AUG2020 28SEP2020	03JUL2020	06JUL2020	27JUL2020	24AUG2020			
	20177	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	03JUL2020 14JUL2020 18AUG2020 28SEP2020	03JUL2020	06JUL2020	27JUL2020	24AUG2020			
	20178	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	03JUL2020 13JUL2020 17AUG2020 28SEP2020	03JUL2020	06JUL2020	27JUL2020	24AUG2020			

Program: Lbase_Disposition_1.sas (Page 9 of 20)

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-3: Listing of subjects disposition - BNT162b2

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
20 µg Younger	20179	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	03JUL2020 13JUL2020 17AUG2020 28SEP2020	03JUL2020	06JUL2020	29JUL2020	24AUG2020			
	20180	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	03JUL2020 13JUL2020 10AUG2020 05OCT2020	03JUL2020	13JUL2020	03AUG2020	31AUG2020			
	20183	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	08JUL2020 13JUL2020 10AUG2020 05OCT2020	08JUL2020	13JUL2020	03AUG2020	03SEP2020		05OCT2020	Withdrawal By Subject
30 µg Younger	20127	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	25MAY2020 21JUN2020 14JUL2020 10AUG2020 14SEP2020	25MAY2020	22JUN2020	14JUL2020	10AUG2020			
	20128	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	26MAY2020 22JUN2020 14JUL2020 11AUG2020 15SEP2020	26MAY2020	23JUN2020	14JUL2020	11AUG2020			
Program: Lbase_Dispatch_1.sas (Page 10 of 20)										

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-3: Listing of subjects disposition - BNT162b2

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
30 µg Younger	20134	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	27MAY2020 21JUN2020 15JUL2020 07AUG2020 21SEP2020	27MAY2020	25JUN2020	15JUL2020	13AUG2020			
	20137	3.0, 17 Apr 2020 5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	28MAY2020 22JUN2020 14JUL2020 11AUG2020 15SEP2020	28MAY2020	23JUN2020	14JUL2020	11AUG2020			
	20138	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	08JUN2020 15JUL2020 07AUG2020 17SEP2020	08JUN2020	25JUN2020	15JUL2020	14AUG2020			
	20142	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	08JUN2020 15JUL2020 12AUG2020 17SEP2020	08JUN2020	25JUN2020	15JUL2020	12AUG2020			
	20143	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	08JUN2020 15JUL2020 13AUG2020 17SEP2020	08JUN2020	25JUN2020	15JUL2020	13AUG2020			
Program: Lbase_Dispatch_1.sas (Page 11 of 20)										

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-3: Listing of subjects disposition - BNT162b2

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
30 µg Younger	20144	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	08JUN2020 15JUL2020 13AUG2020 17SEP2020	08JUN2020	25JUN2020	15JUL2020	13AUG2020			
	20145	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	09JUN2020 15JUL2020 13AUG2020 17SEP2020	09JUN2020	25JUN2020	15JUL2020	13AUG2020			
	20149	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	09JUN2020 14JUL2020 12AUG2020 16SEP2020	09JUN2020	22JUN2020	14JUL2020	12AUG2020			
	20150	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	09JUN2020 14JUL2020 11AUG2020 21SEP2020	09JUN2020	23JUN2020	14JUL2020	11AUG2020			
	20155	5.0, 26 MAY 2020 7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	12JUN2020 14JUL2020 11AUG2020 15SEP2020	12JUN2020	23JUN2020	14JUL2020	11AUG2020			

Program: Lbase_Disposition_1.sas (Page 12 of 20)

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-3: Listing of subjects disposition - BNT162b2

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
10 µg Older	10261	7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	05AUG2020 13AUG2020 25SEP2020	05AUG2020	14AUG2020	04SEP2020	02OCT2020			
	10263	7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	05AUG2020 13AUG2020 25SEP2020	05AUG2020	14AUG2020	04SEP2020	02OCT2020			
	10265	7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	05AUG2020 10AUG2020 15SEP2020	05AUG2020	18AUG2020	08SEP2020	06OCT2020			
	10267	7.0, 26 JUN 2020 8.0, 21 JUL 2020	05AUG2020 15SEP2020	05AUG2020	18AUG2020	08SEP2020	06OCT2020			
	10268	7.0, 26 JUN 2020 8.0, 21 JUL 2020 8.0, 21 JUL 2020	05AUG2020 13AUG2020 15SEP2020	05AUG2020	18AUG2020	08SEP2020	06OCT2020			
Program: Lbase_Disposition_1.sas (Page 13 of 20)										

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-3: Listing of subjects disposition - BNT162b2

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
10 µg Older	10269	7.0, 26 JUN 2020	05AUG2020	05AUG2020	18AUG2020	08SEP2020	06OCT2020			
	10275	8.0, 21 JUL 2020 8.0, 21 JUL 2020	12AUG2020 17SEP2020	12AUG2020	20AUG2020	10SEP2020	08OCT2020			
	10276	8.0, 21 JUL 2020 8.0, 21 JUL 2020	12AUG2020 17SEP2020	12AUG2020	20AUG2020	10SEP2020	08OCT2020			
	10277	8.0, 21 JUL 2020 8.0, 21 JUL 2020	12AUG2020 17SEP2020	12AUG2020	20AUG2020	10SEP2020	08OCT2020			
	10279	8.0, 21 JUL 2020 8.0, 21 JUL 2020	12AUG2020 17SEP2020	12AUG2020	20AUG2020	10SEP2020	08OCT2020			
Program: Lbase_Disposition_1.sas (Page 14 of 20)										

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-3: Listing of subjects disposition - BNT162b2

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
10 µg Older	10299	8.0, 21 JUL 2020 8.0, 21 JUL 2020	17AUG2020 17SEP2020	17AUG2020	20AUG2020	10SEP2020	08OCT2020			
	10300	8.0, 21 JUL 2020 8.0, 21 JUL 2020	17AUG2020 17SEP2020	17AUG2020	20AUG2020	10SEP2020	08OCT2020			
20 µg Older	20208	8.0, 21 JUL 2020 8.0, 21 JUL 2020	10AUG2020 14SEP2020	10AUG2020	25AUG2020	14SEP2020	13OCT2020			
	20214	8.0, 21 JUL 2020 8.0, 21 JUL 2020	11AUG2020 14SEP2020	11AUG2020	26AUG2020	14SEP2020	14OCT2020			
	20215	8.0, 21 JUL 2020 8.0, 21 JUL 2020	11AUG2020 22SEP2020	11AUG2020	01SEP2020	22SEP2020				
Program: Lbase_Disp_1.sas (Page 15 of 20)										

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-3: Listing of subjects disposition - BNT162b2

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
20 µg Older	20216	8.0, 21 JUL 2020 8.0, 21 JUL 2020	11AUG2020 14SEP2020	11AUG2020	25AUG2020	14SEP2020	13OCT2020			
	20221	8.0, 21 JUL 2020 8.0, 21 JUL 2020	14AUG2020 22SEP2020	14AUG2020	01SEP2020	22SEP2020				
	20222	8.0, 21 JUL 2020 8.0, 21 JUL 2020	14AUG2020 14SEP2020	14AUG2020	26AUG2020	14SEP2020	14OCT2020			
	20223	8.0, 21 JUL 2020 8.0, 21 JUL 2020	14AUG2020 14SEP2020	14AUG2020	26AUG2020	14SEP2020	14OCT2020			
	20224	8.0, 21 JUL 2020	14AUG2020	14AUG2020	01SEP2020	22SEP2020				
Program: Lbase_Dispatch_1.sas (Page 16 of 20)										

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-3: Listing of subjects disposition - BNT162b2

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
20 µg Older	20225	8.0, 21 JUL 2020 8.0, 21 JUL 2020	14AUG2020 14SEP2020	14AUG2020	26AUG2020	14SEP2020	14OCT2020			
	20226	8.0, 21 JUL 2020 8.0, 21 JUL 2020	19AUG2020 22SEP2020	19AUG2020	01SEP2020	22SEP2020				
	20229	8.0, 21 JUL 2020 8.0, 21 JUL 2020	19AUG2020 22SEP2020	19AUG2020	01SEP2020	22SEP2020				
	20233	8.0, 21 JUL 2020 8.0, 21 JUL 2020	19AUG2020 22SEP2020	19AUG2020	01SEP2020	22SEP2020				
30 µg Older	10272	8.0, 21 JUL 2020 8.0, 21 JUL 2020	12AUG2020 24SEP2020	12AUG2020	04SEP2020	24SEP2020	23OCT2020			
Program: Lbase_Disp_1.sas (Page 17 of 20)										

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-3: Listing of subjects disposition - BNT162b2

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
30 µg Older	10303	8.0, 21 JUL 2020 8.0, 21 JUL 2020	17AUG2020 24SEP2020	17AUG2020	04SEP2020	24SEP2020	23OCT2020			
	10305	8.0, 21 JUL 2020 8.0, 21 JUL 2020	17AUG2020 25SEP2020	17AUG2020	04SEP2020	25SEP2020	23OCT2020			
	10306	8.0, 21 JUL 2020 8.0, 21 JUL 2020	21AUG2020 22SEP2020	21AUG2020	01SEP2020	22SEP2020	20OCT2020			
	10308	8.0, 21 JUL 2020 8.0, 21 JUL 2020	21AUG2020 24SEP2020	21AUG2020	04SEP2020	24SEP2020	23OCT2020			
	10309	8.0, 21 JUL 2020 8.0, 21 JUL 2020	21AUG2020 23SEP2020	21AUG2020	02SEP2020	23SEP2020	21OCT2020			
Program: Lbase_Disp_1.sas (Page 18 of 20)										

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-3: Listing of subjects disposition - BNT162b2

Safety set

Note: This trial is clinically ongoing. The “date of trial completion” is therefore the “date of the end of treatment visit”.

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
30 µg Older	10310	8.0, 21 JUL 2020 8.0, 21 JUL 2020	21AUG2020 23SEP2020	21AUG2020	02SEP2020	23SEP2020	21OCT2020			
	10314	8.0, 21 JUL 2020 8.0, 21 JUL 2020	21AUG2020 23SEP2020	21AUG2020	02SEP2020	23SEP2020	21OCT2020			
	10316	8.0, 21 JUL 2020 8.0, 21 JUL 2020	21AUG2020 22SEP2020	21AUG2020	01SEP2020	22SEP2020	20OCT2020			
	10319	8.0, 21 JUL 2020 8.0, 21 JUL 2020	24AUG2020 24SEP2020	24AUG2020	04SEP2020	24SEP2020	23OCT2020			
	10323	8.0, 21 JUL 2020 8.0, 21 JUL 2020	24AUG2020 24SEP2020	24AUG2020	04SEP2020	24SEP2020	23OCT2020			
Program: Lbase_Disp_1.sas (Page 19 of 20)										

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-1-3: Listing of subjects disposition - BNT162b2

Safety set

Note: This trial is clinically ongoing. The "date of trial completion" is therefore the "date of the end of treatment visit".

Dose group	Subject number	Protocol versions	Dates of informed consent	Date of screening	Date of prime immunization	Date of boost immunization	Date of trial completion	Date of follow-up completion	Date of premature termination	Main reason for premature termination
30 µg Older	10324	8.0, 21 JUL 2020 8.0, 21 JUL 2020	24AUG2020 23SEP2020	24AUG2020	02SEP2020	23SEP2020	21OCT2020			

Program: Lbase_Disposition_1.sas (Page 20 of 20)

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-5-3: Listing of subjects demographics - BNT162b2

Safety set

Dose group	Subject number	Age [years]	Gender	Ethnicity	Race	Height [cm]	Weight [kg]	BMI [kg/m2]
1 µg Younger	20153	47.75	Female	Not Hispanic or Latino	White	173	67.9	22.7
	20154	53.42	Male	Not Hispanic or Latino	White	174	89.4	29.5
	20157	24.17	Male	Not Hispanic or Latino	White	183	91.3	27.3
	20158	34.58	Male	Not Hispanic or Latino	White	184	98.6	29.1
	20160	21.58	Female	Not Hispanic or Latino	White	169	55.7	19.5
	20163	35.67	Male	Not Hispanic or Latino	White	177	82.4	26.3
	20164	32.42	Female	Not Hispanic or Latino	White	172	66.9	22.6
	20166	22.67	Male	Not Hispanic or Latino	White	204	99.1	23.8
	20171	41.58	Female	Not Hispanic or Latino	White	173	69.1	23.1
	20181	39.42	Female	Not Hispanic or Latino	White	173	69.7	23.3
	20188	41.58	Male	Not Hispanic or Latino	White	175	91.4	29.8
	20189	44.92	Male	Not Hispanic or Latino	White	176	80.6	26
3 µg Younger	20176	44.08	Male	Not Hispanic or Latino	White	195	89.9	23.6
	20185	42.42	Female	Not Hispanic or Latino	White	155	71.6	29.8
	20191	26.58	Male	Not Hispanic or Latino	White	177	75.9	24.2
	20192	24.58	Female	Not Hispanic or Latino	White	168	70.5	25
	20193	35.17	Male	Not Hispanic or Latino	White	184	98	28.9
	20194	55.83	Female	Not Hispanic or Latino	White	157	57.2	23.2
	20195	52.17	Male	Not Hispanic or Latino	White	181	76.7	23.4
Program: Lbase_Demo_5.sas (Page 1 of 6)								

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

090177e196971659\Approved\Approved On: 23-Mar-2021 06:32 (GMT)

Listing 16.2.1-5-3: Listing of subjects demographics - BNT162b2

Safety set

Dose group	Subject number	Age [years]	Gender	Ethnicity	Race	Height [cm]	Weight [kg]	BMI [kg/m2]
3 µg Younger	20197	48.08	Female	Not Hispanic or Latino	White	172	65	22
	20200	39.25	Female	Not Hispanic or Latino	White	169	82.9	29
	20201	33.42	Female	Not Hispanic or Latino	White	168	77.9	27.6
	20203	28.58	Female	Not Hispanic or Latino	White	176	83.4	26.9
	20204	45.50	Male	Not Hispanic or Latino	White	184	76	22.4
10 µg Younger	20101	35.75	Male	Not Hispanic or Latino	White	171	72.4	24.8
	20102	30.42	Male	Not Hispanic or Latino	White	171	79	27
	20103	22.50	Female	Not Hispanic or Latino	White	191	91.6	25.1
	20104	45.50	Female	Not Hispanic or Latino	White	169	63.7	22.3
	20105	37.50	Female	Not Hispanic or Latino	White	183	97.1	29
	20110	46.08	Female	Not Hispanic or Latino	White	165	75.1	27.6
	20111	29.08	Female	Not Hispanic or Latino	White	167	67.8	24.3
	20114	19.00	Male	Not Hispanic or Latino	White	173	74.2	24.8
	20116	23.17	Female	Not Hispanic or Latino	White	166	60.6	22
	20117	51.50	Male	Not Hispanic or Latino	White	188	89	25.2
	20118	44.08	Female	Not Hispanic or Latino	White	165	63.8	23.4
20121	36.25	Female	Not Hispanic or Latino	White	174	79	26.1	
20 µg Younger	20156	45.58	Female	Not Hispanic or Latino	White	167	73.4	26.3
	20159	30.92	Male	Not Hispanic or Latino	White	175	85.9	28
Program: Lbase_Demo_5.sas (Page 2 of 6)								

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-5-3: Listing of subjects demographics - BNT162b2

Safety set

Dose group	Subject number	Age [years]	Gender	Ethnicity	Race	Height [cm]	Weight [kg]	BMI [kg/m2]
20 µg Younger	20168	38.17	Female	Not Hispanic or Latino	White	157	61.6	25
	20172	31.33	Female	Not Hispanic or Latino	White	169	70.6	24.7
	20173	49.25	Female	Not Hispanic or Latino	White	172	62.6	21.2
	20174	55.75	Male	Not Hispanic or Latino	White	173	86.7	29
	20175	35.42	Female	Not Hispanic or Latino	White	165	72.2	26.5
	20177	29.42	Female	Not Hispanic or Latino	White	160	56.9	22.2
	20178	53.25	Female	Not Hispanic or Latino	White	172	78.4	26.5
	20179	50.75	Female	Not Hispanic or Latino	White	162	61.5	23.4
	20180	54.67	Female	Not Hispanic or Latino	White	181	90.2	27.5
	20183	38.50	Female	Not Hispanic or Latino	White	167	69.4	24.9
30 µg Younger	20127	55.67	Male	Not Hispanic or Latino	White	189	83.2	23.3
	20128	39.17	Male	Not Hispanic or Latino	White	179	82.3	25.7
	20134	35.75	Male	Not Hispanic or Latino	White	179	86	26.8
	20137	54.92	Male	Not Hispanic or Latino	White	172	81.2	27.4
	20138	43.83	Female	Not Hispanic or Latino	White	171	73.6	25.2
	20142	51.42	Female	Not Hispanic or Latino	White	157	60.6	24.6
	20143	49.08	Male	Not Hispanic or Latino	White	179	81.6	25.5
	20144	45.42	Female	Not Hispanic or Latino	White	175	78	25.5
	20145	45.75	Male	Not Hispanic or Latino	White	186	79	22.8
Program: Lbase_Demo_5.sas (Page 3 of 6)								

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-5-3: Listing of subjects demographics - BNT162b2

Safety set

Dose group	Subject number	Age [years]	Gender	Ethnicity	Race	Height [cm]	Weight [kg]	BMI [kg/m2]
30 µg Younger	20149	54.17	Female	Not Hispanic or Latino	White	160	61.5	24
	20150	41.42	Male	Not Hispanic or Latino	White	180	82.8	25.6
	20155	49.92	Male	Not Hispanic or Latino	White	188	83.6	23.7
10 µg Older	10261	65.25	Male	Not Hispanic or Latino	White	176	67.5	21.8
	10263	65.33	Male	Not Hispanic or Latino	White	179	88.1	27.5
	10265	58.17	Male	Not Hispanic or Latino	White	179	87.7	27.4
	10267	84.00	Male	Not Hispanic or Latino	White	179	75.6	23.6
	10268	56.92	Female	Not Hispanic or Latino	White	178	76.3	24.1
	10269	73.17	Female	Not Hispanic or Latino	White	165	72.2	26.5
	10275	61.08	Male	Not Hispanic or Latino	White	178	78.8	24.9
	10276	68.08	Female	Not Hispanic or Latino	White	154	55.5	23.4
	10277	67.42	Male	Not Hispanic or Latino	White	172	82.4	27.9
	10279	59.75	Male	Not Hispanic or Latino	White	179	91	28.4
	10299	63.92	Male	Not Hispanic or Latino	White	182	78.3	23.6
10300	62.17	Female	Not Hispanic or Latino	White	176	81	26.1	
20 µg Older	20208	71.42	Female	Not Hispanic or Latino	White	167	74.1	26.6
	20214	65.75	Female	Not Hispanic or Latino	White	172	81.6	27.6
	20215	80.58	Female	Not Hispanic or Latino	White	153	57.7	24.6
	20216	70.58	Female	Not Hispanic or Latino	White	162	59.2	22.6
Program: Lbase_Demo_5.sas (Page 4 of 6)								

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

090177e196971659\Approved\Approved On: 23-Mar-2021 06:32 (GMT)

Listing 16.2.1-5-3: Listing of subjects demographics - BNT162b2

Safety set

Dose group	Subject number	Age [years]	Gender	Ethnicity	Race	Height [cm]	Weight [kg]	BMI [kg/m2]
20 µg Older	20221	62.83	Male	Not Hispanic or Latino	White	170	85.3	29.5
	20222	56.75	Male	Not Hispanic or Latino	White	177	84.7	27
	20223	61.67	Male	Not Hispanic or Latino	White	180	77.7	24
	20224	68.33	Female	Not Hispanic or Latino	White	168	64.2	22.7
	20225	68.00	Male	Not Hispanic or Latino	White	185	84.1	24.6
	20226	59.25	Male	Not Hispanic or Latino	White	184	78.1	23.1
	20229	65.83	Female	Not Hispanic or Latino	White	171	74.4	25.4
	20233	59.58	Male	Not Hispanic or Latino	White	185	101.8	29.7
30 µg Older	10272	57.00	Female	Not Hispanic or Latino	White	166	60.4	21.9
	10303	58.42	Female	Not Hispanic or Latino	White	175	79.4	25.9
	10305	61.50	Male	Not Hispanic or Latino	White	180	94.6	29.2
	10306	57.50	Female	Not Hispanic or Latino	White	165	80.1	29.4
	10308	58.58	Male	Not Hispanic or Latino	White	183	84.5	25.2
	10309	68.17	Male	Not Hispanic or Latino	White	176	77.6	25.1
	10310	73.42	Female	Not Hispanic or Latino	White	162	77	29.3
	10314	61.50	Female	Not Hispanic or Latino	White	158	60.6	24.3
	10316	66.42	Male	Not Hispanic or Latino	White	179	90.1	28.1
	10319	67.92	Female	Not Hispanic or Latino	White	165	61	22.4
	10323	67.75	Female	Not Hispanic or Latino	White	166	62.3	22.6
Program: Lbase_Demo_5.sas (Page 5 of 6)								

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-5-3: Listing of subjects demographics - BNT162b2

Safety set

Dose group	Subject number	Age [years]	Gender	Ethnicity	Race	Height [cm]	Weight [kg]	BMI [kg/m2]
30 µg Older	10324	68.25	Female	Not Hispanic or Latino	White	175	82	26.8
Program: Lbase_Demo_5.sas (Page 6 of 6)								

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-7-3: Listing of medical history - BNT162b2

Safety set

Dose group	Subject number	Sequence number	Abnormality/Disease	Preferred term	System organ class	Start date	End date	Ongoing
1 µg Younger	20153	1	menopause	Menopause	Social circumstances	2017	2017	
	20158	1	allergy against fur of cat, mild	Allergy to animal	Immune system disorders	1995		Yes
		2	mild seborrheic dermatitis (scalp)	Seborrhoeic dermatitis	Skin and subcutaneous tissue disorders	2018		Yes
	20163	1	abrasion both knees from bike accident	Road traffic accident	Injury, poisoning and procedural complications	09JUN2020	29JUN2020	
		2	abrasion both knees from bike accident	Skin abrasion	Injury, poisoning and procedural complications	09JUN2020	29JUN2020	
	20164	1	hypothyroidism	Hypothyroidism	Endocrine disorders	01JAN2015	01JUN2019	
	20166	1	prolapsed lumbar disc	Intervertebral disc protrusion	Musculoskeletal and connective tissue disorders	JAN2018	JAN2018	
	20189	1	mild allergy against pollen (birch, mogwart)	Seasonal allergy	Immune system disorders	2010		Yes
3 µg Younger	20176	1	funnel chest	Pectus excavatum	Congenital, familial and genetic disorders	1976		Yes
10 µg Younger	20101	1	vasectomy	Vasectomy	Surgical and medical procedures	01AUG2016	01AUG2016	
	20104	1	dysmenorrhea	Dysmenorrhoea	Reproductive system and breast disorders	1989		Yes
Medical history is coded using MedDRA version 23.0.								
Program: Lbase_Mh_7.sas (Page 1 of 6)								

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-7-3: Listing of medical history - BNT162b2

Safety set

Dose group	Subject number	Sequence number	Abnormality/Disease	Preferred term	System organ class	Start date	End date	Ongoing
10 µg Younger	20104	2	penicillin intolerance	Drug intolerance	General disorders and administration site conditions	01JAN1995		Yes
		3	recurrent backpain	Back pain	Musculoskeletal and connective tissue disorders	2005		Yes
		4	thyroid cyst(right)	Thyroid cyst	Endocrine disorders	01FEB2019	01MAR2019	
	20105	1	allergy against diclofenac(skin reaction)	Drug hypersensitivity	Immune system disorders	1998		Yes
		2	allergy against pollen(hazelnut,birch,alder)	Seasonal allergy	Immune system disorders	1998		Yes
	20110	1	allergy to grass pollen	Seasonal allergy	Immune system disorders	1985		Yes
		2	allergy to phenacetin	Drug hypersensitivity	Immune system disorders	1994		Yes
		3	recurrent headaches	Headache	Nervous system disorders	1986		Yes
		4	tinnitus	Tinnitus	Ear and labyrinth disorders	OCT2011		Yes
		5	tubal ligation	Female sterilisation	Surgical and medical procedures	2005	2005	
20114	1	allergy against grass pollen	Seasonal allergy	Immune system disorders	2018		Yes	
Medical history is coded using MedDRA version 23.0.								
Program: Lbase_Mh_7.sas (Page 2 of 6)								

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-7-3: Listing of medical history - BNT162b2

Safety set

Dose group	Subject number	Sequence number	Abnormality/Disease	Preferred term	System organ class	Start date	End date	Ongoing
10 µg Younger	20116	1	corrective surgery nasal septum	Nasal septal operation	Surgical and medical procedures	AUG2019	AUG2019	
	20117	1	allergy against nickel	Allergy to metals	Immune system disorders	2000		Yes
		2	meniscus surgery left knee	Meniscus operation	Surgical and medical procedures	2016	2016	
		3	mild lactose intolerance	Lactose intolerance	Metabolism and nutrition disorders	2000		Yes
20 µg Younger	20159	1	lactose intolerance	Lactose intolerance	Metabolism and nutrition disorders	2013		Yes
	20168	1	Slight varicosis of the right leg	Varicose vein	Vascular disorders	MAR2018		Yes
	20178	1	menopause	Menopause	Social circumstances	2015	2015	
		2	tooth pain after dental root treatment	Toothache	Gastrointestinal disorders	02JUL2020		Yes
	20179	1	menopause	Menopause	Social circumstances	2019	2019	
	20180	1	menopause	Menopause	Social circumstances	2018	2018	
2		mild knee complaints	Arthralgia	Musculoskeletal and connective tissue disorders	2015		Yes	
Medical history is coded using MedDRA version 23.0.								
Program: Lbase_Mh_7.sas (Page 3 of 6)								

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-7-3: Listing of medical history - BNT162b2

Safety set

Dose group	Subject number	Sequence number	Abnormality/Disease	Preferred term	System organ class	Start date	End date	Ongoing
30 µg Younger	20128	1	allergy against oil of pine needles	Hypersensitivity	Immune system disorders	1985		Yes
	20137	1	lipoma (back)	Lipoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	2018		Yes
	20138	1	removal of 2 naevi (upper back)	Mole excision	Surgical and medical procedures	2018	2018	
	20142	1	hysterectomy	Hysterectomy	Surgical and medical procedures	MAR2007	MAR2007	
		2	menopause	Menopause	Social circumstances	MAR2007	MAR2007	
	20149	1	Menopause	Menopause	Social circumstances	2013	2013	
	20150	1	heartburn	Dyspepsia	Gastrointestinal disorders	2019		Yes
20155	1	allergy against novaminsulfon cutaneous symptoms only	Drug hypersensitivity	Immune system disorders	1984		Yes	
10 µg Older	10267	1	Shingles	Herpes zoster	Infections and infestations	2017	2017	
	10275	1	Hypercholesterinemia	Hypercholesterolaemia	Metabolism and nutrition disorders	2017		Yes
20 µg Older	20208	1	Menopause	Menopause	Social circumstances	1999	1999	
Medical history is coded using MedDRA version 23.0. Program: Lbase_Mh_7.sas (Page 4 of 6)								

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-7-3: Listing of medical history - BNT162b2

Safety set

Dose group	Subject number	Sequence number	Abnormality/Disease	Preferred term	System organ class	Start date	End date	Ongoing
20 µg Older	20214	1	Hysterectomy	Hysterectomy	Surgical and medical procedures	1995	1995	
		2	Menopause	Menopause	Social circumstances	1995	1995	
	20215	1	Menopause	Menopause	Social circumstances	1993	1993	
	20216	1	Menopause	Menopause	Social circumstances	2005	2005	
	20223	1	abrasion right heel and ankle from incident with bicycle	Road traffic accident	Injury, poisoning and procedural complications	01AUG2020		Yes
		2	abrasion right heel and ankle from incident with bicycle	Skin abrasion	Injury, poisoning and procedural complications	01AUG2020		Yes
	20224	1	Menopause	Menopause	Social circumstances	2004	2004	
	20225	1	catheter intervention (obturation of ventricular septum defect)	Catheterisation cardiac	Investigations	OCT2016	OCT2016	
		2	colon inflammation	Colitis	Gastrointestinal disorders	2017	2017	
		3	surgery colon (excision of 10cm)	Colon operation	Surgical and medical procedures	2017	2017	
		4	ventricular septum defect	Ventricular septal defect	Congenital, familial and genetic disorders	02AUG1952	OCT2016	
	Medical history is coded using MedDRA version 23.0.							
Program: Lbase_Mh_7.sas (Page 5 of 6)								

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.

Listing 16.2.1-7-3: Listing of medical history - BNT162b2

Safety set

Dose group	Subject number	Sequence number	Abnormality/Disease	Preferred term	System organ class	Start date	End date	Ongoing
30 µg Older	10324	1	Nephrolithiasis	Nephrolithiasis	Renal and urinary disorders	2018	2018	
Medical history is coded using MedDRA version 23.0.								
Program: Lbase_Mh_7.sas (Page 6 of 6)								

Staburo GmbH. Based on clean SDTM data received on 03NOV2020. Data cut-off: 23OCT2020.